comparemela.com

Latest Breaking News On - Cytokine storm syndrome - Page 1 : comparemela.com

Bluejay Diagnostics, Inc Completes 90 Subjects in Multicenter Clinical Study Addressing Rapid IL-6 Test for COVID-19 Patients in Critical Care

The Investor Summit: Sigyn Therapeutics, Inc Announces Participation in the Q3 Virtual Investor Summit

San Diego, California (Newsfile Corp. - August 23, 2021) - Sigyn Therapeutics, Inc. (OTC Pink: SIGY) today announced that Jim Joyce, Chairman & CEO will be attending the Q3 Virtual Investor Summit.

The Closing Bell Featuring Sigyn Therapeutics

Press release content from Globe Newswire. The AP news staff was not involved in its creation. The Closing Bell Featuring Sigyn Therapeutics Sigyn Therapeutics, Inc.April 21, 2021 GMT The Interactive Videoconference Occurs Today at 4pm Eastern / 1pm Pacific Time SAN DIEGO, April 21, 2021 (GLOBE NEWSWIRE) via NewMediaWire Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), a medical technology company focused on the treatment of life-threatening inflammatory conditions precipitated by Cytokine Storm Syndrome, announces that its Chairman and CEO, Jim Joyce, will be featured on the Closing Bell videoconference hosted by Force Family Offices at 4pm Eastern today.  This interactive event provides investors with an opportunity to talk directly with Mr. Joyce regarding the advancement of Sigyn Therapy™, a novel blood purification technology designed to treat sepsis and other life-threatening conditions that are induced by cytokine storm syndrome.  Also participating in the event will

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.